Raymond James Financial Services Advisors Inc. Invests $191,000 in Genelux Co. (NASDAQ:GNLX)

Raymond James Financial Services Advisors Inc. purchased a new position in Genelux Co. (NASDAQ:GNLX) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 13,627 shares of the company’s stock, valued at approximately $191,000. Raymond James Financial Services Advisors Inc. owned approximately 0.05% of Genelux as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds also recently modified their holdings of the business. Amalgamated Bank grew its stake in shares of Genelux by 250.8% in the third quarter. Amalgamated Bank now owns 1,077 shares of the company’s stock worth $26,000 after purchasing an additional 770 shares in the last quarter. Exchange Traded Concepts LLC grew its stake in shares of Genelux by 34.0% in the fourth quarter. Exchange Traded Concepts LLC now owns 6,201 shares of the company’s stock worth $87,000 after purchasing an additional 1,573 shares in the last quarter. Falcon Wealth Planning grew its stake in shares of Genelux by 20.0% in the fourth quarter. Falcon Wealth Planning now owns 12,000 shares of the company’s stock worth $168,000 after purchasing an additional 2,000 shares in the last quarter. New York State Common Retirement Fund grew its stake in shares of Genelux by 89.5% in the third quarter. New York State Common Retirement Fund now owns 5,495 shares of the company’s stock worth $135,000 after purchasing an additional 2,595 shares in the last quarter. Finally, Barclays PLC lifted its holdings in shares of Genelux by 516.4% in the third quarter. Barclays PLC now owns 3,384 shares of the company’s stock valued at $83,000 after buying an additional 2,835 shares during the period. Institutional investors own 37.33% of the company’s stock.

Genelux Stock Down 0.9 %

Shares of NASDAQ GNLX opened at $3.45 on Thursday. Genelux Co. has a 12 month low of $3.26 and a 12 month high of $40.98. The business has a fifty day simple moving average of $5.86 and a 200-day simple moving average of $10.95.

Genelux (NASDAQ:GNLX) last announced its earnings results on Friday, March 29th. The company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.21) by ($0.04). Equities research analysts forecast that Genelux Co. will post -0.81 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the company. Benchmark restated a “speculative buy” rating and issued a $30.00 price objective on shares of Genelux in a report on Wednesday, April 3rd. HC Wainwright cut their price objective on Genelux from $35.00 to $32.00 and set a “buy” rating for the company in a report on Tuesday, April 2nd.

Insiders Place Their Bets

In other Genelux news, major shareholder Aladar Szalay sold 8,064 shares of the company’s stock in a transaction dated Wednesday, April 24th. The stock was sold at an average price of $3.50, for a total value of $28,224.00. Following the transaction, the insider now directly owns 1,255,730 shares of the company’s stock, valued at approximately $4,395,055. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders have sold a total of 71,078 shares of company stock valued at $250,663 in the last three months. Insiders own 11.70% of the company’s stock.

Genelux Company Profile

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.